Becton Dickinson & Co
BDX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $997.00 | Tnzhcw | Crgtgmnq |
Becton, Dickinson Should See Normalization in 2024 With Alaris' Return
Business Strategy and Outlook
After a tumultuous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years as the testing revenue fades. As Alaris has now returned to the market, the last remaining uncertainty has been resolved, although it is still to be seen whether the damage experienced by the franchise will be long-lasting or whether Alaris can regain its market-leading share rapidly.